Literature DB >> 28861151

microRNA-204 modulates chemosensitivity and apoptosis of prostate cancer cells by targeting zinc-finger E-box-binding homeobox 1 (ZEB1).

Guanlin Wu1, Jian Wang1, Guojun Chen1, Xing Zhao2.   

Abstract

Epigenetic gene inactivation by microRNAs (miRNAs) is crucial in malignant transformation, prevention of apoptosis, development of drug resistance, and metastasis. miR-204 dysregulation has been reported in prostate cancer (PC). It is considered to exert tumor suppressor functions and is associated with the development of chemoresistance. However, the detailed mechanisms underlying the role of miR-204 in PC, particularly in chemoresistance, remain to be fully elucidated. In this study, analysis using miRNA microarray showed that miR-204 is downregulated in chemoresistant PC tissues with respect to its expression in chemosensitive PC tissues and benign prostatic hyperplasia tissues. Microarray results were validated via qPCR. The changes in miR-204 expression levels were also observed in vitro. Forced overexpression of miR-204 evidently attenuated docetaxel chemoresistance and promoted apoptosis in PC-3-R cells, whereas miR-204 knockdown effectively reduced docetaxel-induced cell death and inhibited cell apoptosis. Mechanistically, miR-204 directly targets the 3'-untranslated region of zinc-finger E-box-binding homeobox 1 (ZEB1) and inhibits its protein expression via translational repression. Furthermore, suppression of ZEB1 could effectively improve miR-204 deficiency-triggered chemoresistance in PC cells. Our results collectively indicate that miR-204 expression is downregulated in chemoresistant PC tissues and cells and that miR-204/ZEB1 could potentially be used as adjunct therapy for patients with advanced/chemoresistant PC.

Entities:  

Keywords:  Prostate cancer; chemoresistant; docetaxel; miR-204; zinc-finger E-box-binding homeobox 1

Year:  2017        PMID: 28861151      PMCID: PMC5575174     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  35 in total

1.  Normalization of cDNA microarray data.

Authors:  Gordon K Smyth; Terry Speed
Journal:  Methods       Date:  2003-12       Impact factor: 3.608

2.  Mechanisms and functional consequences of PDEF protein expression loss during prostate cancer progression.

Authors:  David P Turner; Victoria J Findlay; Omar Moussa; Victor I Semenchenko; Patricia M Watson; Amanda C LaRue; Mohamed M Desouki; Mostafa Fraig; Dennis K Watson
Journal:  Prostate       Date:  2011-03-28       Impact factor: 4.104

3.  miR-128 modulates chemosensitivity and invasion of prostate cancer cells through targeting ZEB1.

Authors:  Xianglun Sun; Youkong Li; Jie Yu; Hong Pei; Pengcheng Luo; Jie Zhang
Journal:  Jpn J Clin Oncol       Date:  2015-03-25       Impact factor: 3.019

4.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

5.  Zeb1 promotes androgen independence of prostate cancer via induction of stem cell-like properties.

Authors:  Ping Li; Jia Wang; Mingliang Chu; Kaiqing Zhang; Ru Yang; Wei-Qiang Gao
Journal:  Exp Biol Med (Maywood)       Date:  2014-06-09

6.  Castration-resistant prostate cancer: AUA Guideline.

Authors:  Michael S Cookson; Bruce J Roth; Philipp Dahm; Christine Engstrom; Stephen J Freedland; Maha Hussain; Daniel W Lin; William T Lowrance; Mohammad Hassan Murad; William K Oh; David F Penson; Adam S Kibel
Journal:  J Urol       Date:  2013-05-09       Impact factor: 7.450

Review 7.  Review of miR-200b and cancer chemosensitivity.

Authors:  Bing Feng; Rui Wang; Long-Bang Chen
Journal:  Biomed Pharmacother       Date:  2012-06-29       Impact factor: 6.529

8.  The ERK-ZEB1 pathway mediates epithelial-mesenchymal transition in pemetrexed resistant lung cancer cells with suppression by vinca alkaloids.

Authors:  L-Y Chiu; I-L Hsin; T-Y Yang; W-W Sung; J-Y Chi; J T Chang; J-L Ko; G-T Sheu
Journal:  Oncogene       Date:  2016-06-06       Impact factor: 9.867

9.  MicroRNA-204 modulates colorectal cancer cell sensitivity in response to 5-fluorouracil-based treatment by targeting high mobility group protein A2.

Authors:  Haijun Wu; Yu Liang; Lin Shen; Liangfang Shen
Journal:  Biol Open       Date:  2016-05-15       Impact factor: 2.422

Review 10.  Role of microRNAs in the resistance of prostate cancer to docetaxel and paclitaxel.

Authors:  Ewa Kopczyńska
Journal:  Contemp Oncol (Pozn)       Date:  2016-01-13
View more
  18 in total

1.  MiR-101 inhibits the proliferation and metastasis of lung cancer by targeting zinc finger E-box binding homeobox 1.

Authors:  Le Han; Wenjuan Chen; Yanmin Xia; Yangrong Song; Zheng Zhao; Hao Cheng; Tao Jiang
Journal:  Am J Transl Res       Date:  2018-04-15       Impact factor: 4.060

2.  MicroRNA-342 inhibits cell proliferation and invasion in nasopharyngeal carcinoma by directly targeting ZEB1.

Authors:  Xiaoning Zhu; Wei Li; Renxian Zhang; Yutao Liu
Journal:  Oncol Lett       Date:  2018-05-22       Impact factor: 2.967

3.  MicroRNA-1294 inhibits the proliferation and enhances the chemosensitivity of glioma to temozolomide via the direct targeting of TPX2.

Authors:  Hua Chen; Liang Liu; Xiaojian Li; Yan Shi; Ning Liu
Journal:  Am J Cancer Res       Date:  2018-02-01       Impact factor: 6.166

4.  MicroRNA-188 inhibits proliferation migration and invasion of prostate carcinoma by targeting at MARCKS.

Authors:  Yao Zhang; Wen Zhang; Aiming Xu; Ye Tian; Chao Liang; Zengjun Wang
Journal:  Am J Transl Res       Date:  2019-08-15       Impact factor: 4.060

Review 5.  Role of noncoding RNA in drug resistance of prostate cancer.

Authors:  Lifeng Ding; Ruyue Wang; Danyang Shen; Sheng Cheng; Huan Wang; Zeyi Lu; Qiming Zheng; Liya Wang; Liqun Xia; Gonghui Li
Journal:  Cell Death Dis       Date:  2021-06-08       Impact factor: 8.469

6.  MiR-361-5p suppresses chemoresistance of gastric cancer cells by targeting FOXM1 via the PI3K/Akt/mTOR pathway.

Authors:  Lei Tian; Zhifeng Zhao; Ling Xie; JinPeng Zhu
Journal:  Oncotarget       Date:  2017-12-20

7.  Long non-coding RNA PCAT6 targets miR-204 to modulate the chemoresistance of colorectal cancer cells to 5-fluorouracil-based treatment through HMGA2 signaling.

Authors:  Haijun Wu; Qiongyan Zou; Hong He; Yu Liang; Mingjun Lei; Qin Zhou; Dan Fan; Liangfang Shen
Journal:  Cancer Med       Date:  2019-04-01       Impact factor: 4.452

8.  Expression and potential molecular mechanisms of miR‑204‑5p in breast cancer, based on bioinformatics and a meta‑analysis of 2,306 cases.

Authors:  Kai-Teng Cai; An-Gui Liu; Ze-Feng Wang; Hang-Wei Jiang; Jing-Jing Zeng; Rong-Quan He; Jie Ma; Gang Chen; Jin-Cai Zhong
Journal:  Mol Med Rep       Date:  2018-12-14       Impact factor: 2.952

9.  microRNA-211-mediated targeting of the INHBA-TGF-β axis suppresses prostate tumor formation and growth.

Authors:  Zhifeng Zhao; Kai Wang; Shanfeng Tan
Journal:  Cancer Gene Ther       Date:  2020-11-22       Impact factor: 5.854

10.  Dicer affects cisplatin‑mediated apoptosis in epithelial ovarian cancer cells.

Authors:  Xi Wang; Hui Chen; Yiping Wen; Xiaoxin Yang; Qing Han; Ping Jiang; Zaiju Huang; Jing Cai; Zehua Wang
Journal:  Mol Med Rep       Date:  2018-09-04       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.